• It was a bad day for Genzyme and GSK as the economy and generic erosion, well, eroded their Q1 earnings, respectively. [Bloomberg], [WSJ]

• The gloves are coming off as Carl Icahn and Amylin Pharmaceuticals have ended talks to settle a proxy battle. [Forbes]

• Immtech Pharmaceuticals is reorganizing its R&D and axing its CMO. [PR Newswire]

• Tranzyme Pharma said its drug TZP-101 for gastroparesis was effective in a mid-stage trial. Now what? [FierceBiotech]

• Pfizer and Medicines for Malaria Venture have signed an agreement to screen for compounds that could be effective against malaria. [EarthTimes]

• Pharmos raises $1.8M in private placement from NEA and Venrock Associates. [TradingMarkets]

• Finally, the FDA will allow 17-year-olds to get the ‘morning-after’ birth control pill without a doctor’s prescription. [Google]

Image from unh

Related Posts